COMMUNIQUÉS West-GlobeNewswire

Intra-Cellular Therapies Presents Data on Lumateperone, ITI-214 and ITI-333 at the 56th Annual Meeting of the American College of Neuropsychopharmacology
07/12/2017
NEW YORK, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI ), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today [...]
Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
07/12/2017
Copenhagen, 2017-12-07 13:51 CET (GLOBE NEWSWIRE) -- ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ) reports the following transactions: 1. Details of the person discharging managerial responsibility / person closely [...]
Beleave Signs Brand Licensing Agreement with Kevin Smith & Jason Mewes
07/12/2017
TORONTO, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Beleave Inc. (" Beleave " or the " Company ") (CSE:BE) (OTCQX:BLEVF) is pleased to announce that it has entered into a Brand Licensing Agreement with Kevin Smith and Jason [...]
INC Research/inVentiv Health Strengthens Leadership of Commercial Solutions
07/12/2017
RALEIGH, N.C., Dec. 07, 2017 (GLOBE NEWSWIRE) -- INC Research/inVentiv Health (NASDAQ: INCR ), the only fully integrated biopharmaceutical solutions organization combining a CRO and a CCO (Contract Commercial [...]
Immunovaccine and UConn Health Extend Collaboration to Support Advancement of Patient-Specific Immunotherapies to the Clinic
07/12/2017
HALIFAX, Nova Scotia, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (“Immunovaccine” or the “Company”) (TSX: IMV ) (OTCQX:IMMVF), a clinical stage immunotherapy and vaccine company, today announced an expansion [...]
ObsEva SA to Participate in BMO Healthcare Conference December 14th 2017
07/12/2017
Geneva, Switzerland and Boston, MA -December 7, 2017 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions [...]
Fibrocell Announces Pricing of $10.5 Million Underwritten Public Offering
07/12/2017
EXTON, Pa., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC ), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today [...]
Advanced Accelerator Applications Announces Commencement of Novartis Tender Offer
07/12/2017
SAINT-GENIS-POUILLY, France, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ: AAAP ) (AAA or the Company), a leader in nuclear medicine theragnostics, today announced that a direct and [...]
Akcea to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
07/12/2017
CAMBRIDGE, Mass., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA ), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious [...]
CRISPR Therapeutics Submits First Clinical Trial Application for a CRISPR Gene-Edited Therapy, CTX001 in β-thalassemia
07/12/2017
ZUG, Switzerland and CAMBRIDGE, Mass., Dec. 07, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP ) today announced the submission of a Clinical Trial Application (CTA) for CTX001 in β-thalassemia. CTX001 is an [...]
Nightstar Therapeutics to Participate in BMO Prescriptions for Success Healthcare Conference
07/12/2017
LEXINGTON, Mass. and LONDON, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ: NITE ), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced [...]
Pluristem to Present Data on PLX-R18 in Treatment of Acute Radiation Syndrome at American Society of Hematology’s Annual Meeting
07/12/2017
Data from Phase II-equivalent study demonstrated improved survival and hematological recovery of non-human primates (NHP) exposed to high levels of radiation PLX-R18 cells are in late-stage development as a treatment [...]
SuperSonic Imagine Installs Six Aixplorer® Ultimate Ultrasound Systems at 'Occitanie-Garonne' Medical Imaging Group
07/12/2017
AIX-EN-PROVENCE, France, Dec. 07, 2017 (GLOBE NEWSWIRE) -- SuperSonic Imagine (Euronext:SSI FR0010526814), a company specialising in medical imaging using ultrasound, announced today that it installed six Aixplorer [...]
Tresiba® reduces hypoglycaemia regardless of blood sugar level
07/12/2017
Abu Dhabi, UAE, 7 December 2017 - People with either type 1 or type 2 diabetes treated with Tresiba ® had fewer episodes of low blood sugar (hypoglycaemia) compared with people on insulin glargine U100 regardless of [...]
Ryzodeg® significantly reduces the risk of low blood sugar in people with type 2 diabetes who fast during Ramadan
07/12/2017
Abu Dhabi, UAE, 7 December 2017 - In people with type 2 diabetes who fast during Ramadan, Ryzodeg ® (insulin degludec/insulin aspart) reduced the overall rate of low blood sugar (hypoglycaemia) including severe [...]
PRICING AND FURTHER DETAILS ON THE OFFERING OF NEW SHARES IN ALK-ABELLÓ A/S
07/12/2017
Copenhagen, 2017-12-07 08:01 CET (GLOBE NEWSWIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, [...]
OSE Immunotherapeutics to Resume Accrual in Phase 3 Clinical Trial of Tedopi® in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment
07/12/2017
Independent Data Monitoring Committee recommends future recruitment focused on patients who have previously failed immune checkpoint inhibitor treatment New strategy adjusts for rapidly-evolving clinical practice with [...]
ABLYNX WILL HOST A WEBCAST TO DISCUSS ADDITIONAL DATA FROM ITS PHASE III HERCULES STUDY OF CAPLACIZUMAB IN ACQUIRED TTP FOLLOWING ASH LATE-BREAKING DATA PRESENTATION
07/12/2017
GHENT, Belgium, 7 December 2017 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX] announced today that the Ablynx management team will host a conference call and webcast to present additional data from the Phase III [...]
Novartis tender offer for Advanced Accelerator Applications commences
07/12/2017
Basel, December 7, 2017 - Novartis AG (NYSE: NVS) ("Novartis") today announced that its direct and indirect subsidiary, Novartis Groupe France S.A., a société anonyme organized under the laws of France ("Purchaser"), [...]

Pages